Pharmacologically active IL-13 inhibitors, such as pitrakinra (an IL-4 mutant), tralokinumab, or the soluble IL-13Rα2, have already been clinically tested for the treatment of other diseases, such as asthma or in tumor therapy. This evidence concerns the gene IL13RA2 and neoplasm.